Subq vs. IM Testosterone: what the PK data actually shows

If you're on testosterone replacement — or about to start — the choice of injection route is not cosmetic. Subcutaneous (subq) and intramuscular (IM) injections deliver the same drug, but the pharmacokinetic curves differ enough to shape how you feel, how your estradiol behaves, and how often you need to inject.

Here's what the data actually says, and how a clinician thinks through the choice.

What's actually different between subq and IM?

The tissue, not the drug.

Both routes typically use testosterone cypionate or enanthate — the same oil-based esters. IM injection deposits the oil into muscle tissue (glute, quad, ventroglute, or deltoid), where a rich blood supply pulls the ester into circulation relatively quickly. Subq injection places the oil into the fat layer just under the skin (abdomen, flank, or thigh), where blood flow is lower and absorption is slower.

Slower absorption is the whole point. It's not a different medication — it's a different release curve.

Does subcutaneous testosterone actually work? What the studies show

Yes, and the PK is arguably better.

The pivotal PK study is Kaminetsky et al. (2019), which compared subq testosterone enanthate to historical IM data. Weekly subq dosing produced serum testosterone within the eugonadal range in over 90% of participants, with mean trough levels around 400–500 ng/dL and peaks that stayed well below supraphysiologic territory.

A 2018 study by Spratt et al. in transgender men on subq testosterone cypionate found similar results: stable levels, predictable absorption, no clinical inferiority to IM.

A 2022 randomized comparison (Turner et al.) found subq injection produced lower peak testosterone and higher trough testosterone than the same weekly dose given IM — a flatter curve, in other words. Total AUC (area under the curve — the overall exposure) was comparable.

Same dose, same drug, flatter curve. That's the subq trade in one sentence.

Peaks, troughs, and why the curve shape matters

This is where symptoms live.

With weekly IM cypionate, serum testosterone typically peaks 24–48 hours post-injection and troughs right before the next dose. If the peak is high (say, 1,200+ ng/dL) and the trough is low (say, 300 ng/dL), you get a real rollercoaster: energy and libido surge for a few days, then drop.

Aromatization — the conversion of testosterone to estradiol via the aromatase enzyme — is dose-dependent and roughly tracks the peak. Higher peaks mean more estradiol spikes, which for some men means water retention, nipple sensitivity, or mood swings 48–72 hours post-injection.

Subq, by flattening the peak, tends to:

• Reduce peak-driven estradiol spikes
• Reduce hematocrit rise (though this is less well-established and still needs monitoring)
• Smooth out the mid-week energy dip
• Make twice-weekly or every-other-day dosing feel almost continuous

IM has its own advantages: a faster onset if you're starting therapy and want to feel the shift quickly, and it's the route with the longest track record and the most prescriber familiarity.

Is subq less painful? What patients actually report

Mostly yes — but individual anatomy matters.

Subq uses a smaller, shorter needle — typically a 27–30 gauge, 1/2 inch insulin-style syringe. IM requires a 22–25 gauge, 1–1.5 inch needle to reach muscle. On paper, subq is less invasive.

Most patients report less post-injection soreness with subq. The trade-off is that some people develop small, temporary lumps or redness at the subq site as the oil slowly absorbs — usually harmless and resolves within a few days. Rotating sites (left flank, right flank, left thigh, right thigh) prevents cumulative irritation.

IM injection, done correctly, is quick and rarely painful — but a mis-angled shot into a tendon or nerve area can leave you sore for a week. There's a modest learning curve.

Dosing frequency: does subq let you inject less often?

Sometimes the opposite, actually.

Because subq flattens the curve, some clinicians and patients prefer more frequent, smaller doses — twice weekly or every other day — to keep levels rock-steady. Others do fine on once-weekly subq.

IM is often done once weekly or twice weekly. Going to once every two weeks (a legacy dosing pattern) tends to produce the biggest peaks and deepest troughs, and most modern TRT protocols have moved away from it.

There is no single "right" frequency. It depends on your ester (cypionate vs. enanthate have slightly different half-lives), your dose, and how your labs and symptoms track together.

{callout: The bottom line} At the same weekly dose, subcutaneous testosterone injections produce a flatter pharmacokinetic curve than intramuscular — lower peaks, higher troughs, similar total exposure. For many patients, that translates to steadier symptoms and less estradiol volatility.

What labs matter when you're comparing routes?

Tuned to your numbers, not someone else's.

The markers worth having when you're on TRT — regardless of route — typically include:

• Total testosterone (trough, ideally, drawn right before your next dose)
• Free testosterone (the bioavailable fraction)
• Estradiol (sensitive assay, not the standard immunoassay)
• Hematocrit and hemoglobin (TRT can raise red cell mass; hematocrit above ~54% often prompts a dosing adjustment)
• SHBG (sex hormone binding globulin — affects how much testosterone is free vs. bound)
• PSA in men over 40

If you choose to run labs through us, these are the markers we look at first when someone is deciding between subq and IM or troubleshooting how they feel on their current protocol. Trough timing matters — a total T drawn 24 hours after injection tells you almost nothing useful about your steady-state level.

So which route should you choose?

In plain English.

There's no universally superior route. The evidence supports both. A reasonable framework:

• Consider subq if: you want the flattest curve, you've had estradiol issues on IM, you dislike larger needles, or you're comfortable with self-injection multiple times per week.
• Consider IM if: you prefer once-weekly dosing, your prescriber is more experienced with IM protocols, or you've tried subq and had absorption or site-reaction issues.

Both routes benefit from the same thing: a clinician who reviews your symptoms, history, and — when you run them — your labs, and adjusts the plan based on how you actually respond. Standard published titration ranges for testosterone cypionate in men typically fall between 100–200 mg per week total, split or single-dose, with adjustments based on trough levels and clinical response.

Compounded testosterone (which is what most injectable TRT in the U.S. direct-care space is) is not FDA-approved as a finished product — that's covered in the site disclaimer, and it's worth understanding before you start.

The honest summary

Subq is not a gimmick. It's a legitimately different pharmacokinetic profile that many patients — and a growing number of clinicians — prefer for its stability. IM is not outdated. It's a well-understood route with decades of data and can be dialed in beautifully with the right frequency.

Pick the one that fits your anatomy, your schedule, your needle tolerance, and — most importantly — the curve your body seems to respond to best. That last part only becomes clear a few weeks in, when you look at your trough labs and how you actually feel between shots.

References

• Kaminetsky JC, et al. Subcutaneous testosterone enanthate weekly injection: pharmacokinetics and safety. J Urol. 2019.
• Spratt DI, et al. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection. J Clin Endocrinol Metab. 2017.
• Turner L, et al. Comparison of subcutaneous and intramuscular testosterone pharmacokinetics. Andrology. 2022.
• Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. 2018.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.